Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Daniel E. Falk"'
Autor:
Megan L. Ryan, Stephanie S. O’Malley, Joanne B. Fertig, Raye Z. Litten, Daniel E. Falk, Srinivas B. Muvvala, Hayley Treloar Padovano, Ran Wu, Thomas H. Chun, Robert Miranda
Publikováno v:
Alcohol Clin Exp Res
BACKGROUND: The alcohol cue reactivity paradigm is increasingly used to screen medications for the treatment of alcohol use disorder (AUD) and other substance use disorders. Yet, its prospective association with craving and naturalistic drinking outc
Autor:
Henry R. Kranzler, Deborah S. Hasin, Katie Witkiewitz, Karl Mann, Raymond F. Anton, Stephanie S. O'Malley, Nick Heather, Raye Z. Litten, Daniel E. Falk
Publikováno v:
Addiction. 115:1668-1680
Aims To examine whether World Health Organization (WHO) risk-level reductions in drinking were achievable, associated with improved functioning and maintained over time among patients at varying initial alcohol dependence severity levels. Design and
Publikováno v:
Alcoholism: Clinical and Experimental Research. 44:23-35
Autor:
Raymond F. Anton, Raye Z. Litten, Katie Witkiewitz, Deborah S. Hasin, Stephanie S. O'Malley, Henry R. Kranzler, Karl Mann, Daniel E. Falk
Publikováno v:
Alcoholism, Clinical and Experimental Research
BACKGROUND Reductions in the World Health Organization (WHO) risk drinking levels have been proposed as an alternative primary outcome for alcohol clinical trials. Yet, little is known about whether reductions in WHO risk drinking levels can be maint
Autor:
Raye Z. Litten, Deborah S. Hasin, Henry R. Kranzler, Katie Witkiewitz, Raymond F. Anton, Karl Mann, Kevin A. Hallgren, Stephanie S. O'Malley, Daniel E. Falk
Publikováno v:
Alcoholism: Clinical and Experimental Research. 42:2453-2465
BACKGROUND. Abstinence and no heavy drinking days are currently the only Food and Drug Administration (FDA) approved endpoints in clinical trials for alcohol use disorder (AUD). Many individuals who fail to meet these criteria may substantially reduc
Autor:
Henry R. Kranzler, Jennifer Scodes, Stephanie S. O'Malley, Justin Knox, Katie Witkiewitz, Karl Mann, Raymond F. Anton, Deborah S. Hasin, Raye Z. Litten, Daniel E. Falk, Melanie M. Wall
Publikováno v:
Alcoholism: Clinical and Experimental Research. 42:2256-2265
Background Abstinence is often the treatment aim for alcohol use disorders (AUD), but this may deter individuals who prefer drinking reduction goals from entering treatment, and be an overly restrictive end point in alcohol clinical trials. Nonabstin
Autor:
Megan L. Ryan, Raymond F. Anton, Joanne B. Fertig, Jennifer Scodes, Francoise Trinquet, Keith Isenberg, Daniel E. Falk, Karl Mann, Rebecca L. Robinson, Henry R. Kranzler, Charles A. O'Brien, Bernard L. Silverman, David J. McCann, Roger E. Meyer, Conrad J. Wong, Katie Witkiewitz, Melanie M. Wall, Didier Meulien, Deborah S. Hasin, Benjamine Zakine, Stephanie S. O'Malley, Raye Z. Litten
Publikováno v:
The Lancet Psychiatry. 4:469-476
Summary Background Alcohol dependence is often untreated. Although abstinence is often the aim of treatment, many drinkers prefer drinking reduction goals. Therefore, if supported by evidence of benefit, drinking reduction goals could broaden the app
Publikováno v:
Alcoholism, clinical and experimental research, vol 41, iss 3
Author(s): Kline-Simon, Andrea H; Litten, Raye Z; Weisner, Constance M; Falk, Daniel E | Abstract: BackgroundTreatment for alcohol use disorders (AUDs) has traditionally been abstinence oriented, but new research and regulatory guidelines suggest tha
Autor:
Katie Witkiewitz, Deborah S. Hasin, Daniel E. Falk, Stephanie S. O'Malley, Raymond F. Anton, Kevin A. Hallgren, Henry R. Kranzler, Karl Mann, Raye Z. Litten
Publikováno v:
Alcoholism, Clinical and Experimental Research
Background Alcohol use disorder (AUD) is a highly prevalent public health problem associated with considerable individual and societal costs. Abstinence from alcohol is the most widely accepted target of treatment for AUD, but it severely limits trea
Publikováno v:
Handbook of experimental pharmacology. 258
Compared to other medical disorders, including other brain diseases, the number of medications approved for alcohol use disorder (AUD) is very small. Disulfiram, naltrexone (oral and long-acting), and acamprosate are approved by the US Food and Drug